Oramed Pharmaceuticals
ORMP
25 hedge funds and large institutions have $1.31M invested in Oramed Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
85% more call options, than puts
Call options by funds: $265K | Put options by funds: $143K
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4% less funds holding
Funds holding: 26 → 25 (-1)
27% less capital invested
Capital invested by funds: $1.78M → $1.31M (-$475K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$74.2K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
+$34.1K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$9.41K |
| 4 |
DLHL
Donald L. Hagan LLC
Sarasota,
Florida
|
+$6.7K |
| 5 |
JIC
Joel Isaacson & Co
New York
|
+$4.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$123K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$52.2K |
| 3 |
GIM
Greylin Investment Management
Orange,
Virginia
|
-$32.5K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$16.2K |
| 5 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
-$6.84K |
ORMP Hedge Fund Activity: Q1 2016 in Review
25 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2016, worth a combined $1.31M — down 27% from $1.78M a quarter earlier.
Fund positioning in ORMP was balanced in Q1 2016: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 5 trimmed.
The largest buyer was PNC Financial Services Group, adding an estimated $74.2K. The largest seller was Millennium Management, exiting entirely with an estimated $123K sold.
- 25 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2016, down from 26 in Q4 2015.
- Funds reported $1.31M of Oramed Pharmaceuticals stock for Q1 2016, down 27% quarter-over-quarter.
- 3 funds opened new Oramed Pharmaceuticals positions in Q1 2016 and 3 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2016 was PNC Financial Services Group, an estimated $74.2K added.
- The largest Oramed Pharmaceuticals seller in Q1 2016 was Millennium Management, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2016.